SciBase – Unique method for detecting malignant melanoma

SciBase, which started as a research project at KarolinskaInstitutet, has developed a unique product called Nevisense for the detection of malignant melanoma.

Business activities

The patented Nevisense diagnosis technique sends electrical impulses at different frequencies through the area of skin under examination. An algorithm trained to identify malignancy provides information within a few seconds on the extent of the malignancy of the lesion.The method has demonstrated very good results in extensive clinical studies, the most recent of which conducted at 22 clinics in Europe and the USA constitutes the largest study ever carried out in this field.

The new technique gives physicians a tool that can objectively measure the risk of changes in lesions being malignant. The method will save costs in the care chain as unnecessary and costly procedures and analysis can be avoided. At the same time, the technique can identify melanoma that may be wrongly diagnosed with the visual methods used today. The results from the studies underscore the fact that Nevisense can contribute to easier and earlier detection of malignant melanoma and thereby potentially save lives. Scibase was listed on Nasdaq First North in June 2015.

Market

  • Malignant melanoma is the fastest growing form of cancer and, if not detected in time, is also one of the deadliest. Early diagnosis is critical for the patient’s survival. There are also major healthcare cost savings to be made with more reliable diagnosis
  • Worldwide, around 160,000 new cases of melanomaare diagnosed every year, and in Sweden alone, around 3,300 cases a year are reported
  • Annually, some 50–60 million examinations are carried out globally and around 10 percent of skinlesions are removed and sent for analysis
  • Notably, more than 95 percent of these are completely benign, which represents an unnecessary cost burden in the healthcare system

Significant events during the year

  • Nevisense View was launched and sales started. The new product has an integrated feature for imaging and versal handling
  • Cooperation with Demoscan in Germany for joint marketing of an integrated workflow for digital dermaskopy and Nevisense
  • Sales and use per installed Nevisense increases in Germany
  • Closing actions for the FDA process submitted